Advertisement

Malignant Phonic Tics

  • Carolyn Kwak
  • Joseph Jankovic
Part of the Current Clinical Neurology book series (CCNEU)

Abstract

The following five patients illustrate the problem of malignant motor tics. Patient 1: Patient with Gilles de la Tourette’s syndrome (GTS) who, in addition to motor tics, exhibits loud vocalizations and screams which have markedly impaired his quality life. His mother has only blinking tics.

Keywords

Botulinum Toxin Tourette Syndrome Acad Child Adolesc Psychiatry Left Vocal Cord Tourette Syndrome Patient 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Kurlan R, Como PG, Miller B, et al. The behavioral spectrum of tic disorders: a community-based study. Neurology 2002;59:414–420.PubMedGoogle Scholar
  2. 2.
    Snider LA, Seligman LD, Ketchen BR, et al. Tics and problem behaviors in schoolchildren: prevalence, characterization, and associations. Pediatrics 2002;110:331–336.PubMedCrossRefGoogle Scholar
  3. 3.
    Jankovic J. Phenomenology and classification of tics. In: Jankovic J, ed. Tourette Syndrome. Neurol Cl N Am, Vol 15. WB Saunders, Philadelphia: 1997;267–275.Google Scholar
  4. 4.
    Jankovic J. Tourette’s syndrome. N Engl J Med 2001;345:1184–1192.PubMedCrossRefGoogle Scholar
  5. 5.
    Leckman J. Tourette’s syndrome. Lancet 2002;360:1577–1586.PubMedCrossRefGoogle Scholar
  6. 6.
    The Tourette Syndrome Classification Study Group. Definitions and classification of tic disorders. Arch Neurol 1993;50:1013–1016.Google Scholar
  7. 7.
    Singer C. Tourette syndrome. Coprolalia and other coprophenomena. Neurol Clin 1997;15:299–308.Google Scholar
  8. 8.
    Goldenberg J, Brown S, Weiner W. Coprolalia in younger patients with Gilles de la Tourette’s syndrome: description and risk factors. Neurology 1992;42:784–788.Google Scholar
  9. 9.
    Krauss JK, Jankovic J. Severe motor tics causing cervical myelopathy in Tourette’s syndrome. Mov Disord 1996;11:563–566.PubMedCrossRefGoogle Scholar
  10. 10.
    Jankovic J, Sekula SL, Milas D. Dermatological manifestations of Tourette’s syndrome and obsessive-compulsive disorder. Arch Dermatol 1998;134:113–114.PubMedCrossRefGoogle Scholar
  11. 11.
    Shapiro A, Shaprio E. Treatment of Gilles de la Tourette’s syndrome with haloperidol. Br J Psychiatry 1968;114:345–350.PubMedCrossRefGoogle Scholar
  12. 12.
    Scott B, Jankovic J, Donovan D. Botulinum toxin into vocal cord in the treatment of malignant coprolalia associated with Tourette’s syndrome. Mov Disord 1996;11:431–433.PubMedCrossRefGoogle Scholar
  13. 13.
    Salloway S, Stewart C, Israeli L. Botulinum toxin for refractory vocal tics. Mov Disord 1996;11:746–748.PubMedCrossRefGoogle Scholar
  14. 14.
    Trimble M, Whurr R, Brookes F, Robertson M. Vocal tics in Gilles de la Tourette syndrome treated with botulinum toxin injections. Mov Disord 1998;13:617–619.PubMedCrossRefGoogle Scholar
  15. 15.
    Mink J. Neurobiology of basal ganglia circuits in Tourette syndrome: faulty inhibition of unwanted motor patterns? In: Cohen D, Jankovic J, Goetz C, eds. Tourette Syndrome, Advances in Neurology, Vol. 85. Lippincott Williams and Wilkins, Philadelphia: 2001; 113–122.Google Scholar
  16. 16.
    Jeffries K, Schooler C, Schoenbach C, Herscovitch P, Chase T, Braun A. The functional neuroanatomy of Tourette’s syndrome: an FDG PET study III: functional coupling of regional cerebral metabolic rates. Neuropsychopharmacology 2002;27:92–104.PubMedCrossRefGoogle Scholar
  17. 17.
    Peterson B, Staib L, Scahill L, et al. Regional brain and ventricular volumes in Tourette syndrome. Arch Gen Psychiatry 2001;58:427–440.PubMedCrossRefGoogle Scholar
  18. 18.
    Lang A. Patient perception of tics and other movement disorders. Neurology 1991;41:223–228.PubMedGoogle Scholar
  19. 19.
    Leckman J, Walker D, Cohen D. Premonitory urges in Tourette’s syndrome. Am J Psychiatry 1993;150:98–102.PubMedGoogle Scholar
  20. 20.
    Scahill L, Leckman J, Marek K. Sensory phenomenon in Tourette’s syndrome. Behavioral Neurology of Movement Disorders. In: Weiner W, Lang A, eds. Advances in Neurology, Vol. 65. Raven, New York: 1995;273–280.Google Scholar
  21. 21.
    Cohen A, Leckman J. Sensory phenomenon associated with Gilles de la Tourette’s syndrome. Clin Psychiatry 1992;53:319–323.Google Scholar
  22. 22.
    Kwak C, Vung KD, Jankovic J. Premonitory sensory phenomenon in Tourette syndrome. Mov Disord 2004 (in press).Google Scholar
  23. 23.
    Jankovic J. Botulinum toxin in the treatment of dystonic tics. Mov Disord 1994;9:347–349.PubMedCrossRefGoogle Scholar
  24. 24.
    Kwak C, Hanna P, Jankovic J. Botulinum toxin in the treatment of tics. Arch Neurol 2000;57:1190–1193.PubMedCrossRefGoogle Scholar
  25. 25.
    Marras C, Andrews D, Sime E, Lang A. Botulinum toxin for simple motor tics: a randomized, double-blind, controlled clinical trial. Neurology 2001;56:605–610.PubMedGoogle Scholar
  26. 26.
    Graybiel A, Aosaki T, Flaherty A. The basal ganglia and adaptive motor control. Science 1994;265:1826–1831.PubMedCrossRefGoogle Scholar
  27. 27.
    Fried I, Katz A, McCarthy G, et al. Functional organization of human supplementary motor cortex studied by electrical stimulation. J Neurosci 1991;11:3656–3666.PubMedGoogle Scholar
  28. 28.
    Jimenez-Jimenez F, Garcia-Ruiz P. Pharmacological options for the treatment of Tourette’s disorder. Drugs 2001;61:2207–2220.PubMedCrossRefGoogle Scholar
  29. 29.
    Singer H. The treatment of tics. Curr Neurol Neurosci Rep 2001;1:195–202.PubMedCrossRefGoogle Scholar
  30. 30.
    Robertson M, Stern J. Gilles de la Tourette syndrome: symptomatic treatment based on evidence. Eur Child Adolesc Psychiatry 2000;9(Suppl 1):160–175.Google Scholar
  31. 31.
    Onofrj M, Paci C, D’Andreamatteo G, Toma L. Olanzapine in severe Gilles de la Tourette syndrome: a 52-week double-blind cross-over study vs. low-dose pimozide. J Neurol 2000;247:443–446.Google Scholar
  32. 32.
    Bruggeman R, van der Linden C, Buitelaar J, Gericke G, Hawkridge S, Temlett J. Risperidone versus pimozide in Tourette’s disorder: a comparative double-blind parallel-group study. J Clin Psychiatry 2001;62:50–56.PubMedCrossRefGoogle Scholar
  33. 33.
    Sallee F, Kurlan R, Goetz C, et al. Ziprasidone treatment of children and adolescents with Tourette’s syndrome: a pilot study. J Am Acad Child Adolesc Psychiatry 2000;29:292–299.CrossRefGoogle Scholar
  34. 34.
    Jankovic J, Beach J. Long-term effects of tetrabenazine in hyperkinetic movement disorders. Neurology 1997;48:358–362.PubMedGoogle Scholar
  35. 35.
    Hunter CB, Wang A, Vuong KD, Jankovic J. Tetrabenazine in the treatment of Tourette syndrome. Mov Disord 2002;17(Suppl 5):S341.Google Scholar
  36. 36.
    Scahill L, Chappell P, Kim Y, Schultz R, et al. A placebo-controlled study of guanfacine in the treatment of children with tic disorders and attention deficit hyperactivity disorder. Am J Psychiatry 2001;158:1067–1074.PubMedCrossRefGoogle Scholar
  37. 37.
    Gaffney G, Perry P, Lund B, Bever-Stille K, Arndt S, Kuperman S. Risperidone versus clonidine in the treatment of children and adolescents with Tourette’s syndrome. J Am Acad Child Adolesc Psychiatry 2002;41:330–336.PubMedCrossRefGoogle Scholar
  38. 38.
    Muller-Vahl K, Schneider U, Koblenz A, et al. Treatment of Tourette’s syndrome with Delta 9-tetrahydrocannabinol (THC): A randomized crossover trial. Pharmacopsychiatry 2002;35:57–61.PubMedCrossRefGoogle Scholar
  39. 39.
    Piacentini J, Chang S. Behavioral treatments for Tourette syndrome and tic disorders: state of the art. Adv Neurol 2001;85:319–331.PubMedGoogle Scholar
  40. 40.
    Bergin A, Waranch H, Borwn J, Carson K, Singer H. Relaxation therapy in Tourette syndrome: a pilot study. Pediatr Neurol 1998;18:136–142.PubMedCrossRefGoogle Scholar
  41. 41.
    Evers R van de Wetering B. A treatment model for motor tics based on a specific tension-reduction technique. J Behav Ther Exp Psychiatry 1994;25:255–260.PubMedCrossRefGoogle Scholar
  42. 42.
    Hsiung G, Das S, Ranawaya R, Lafontaine A, Suchowersky O. Long-term efficacy of botulinum toxin A in treatment of various movement disorders over a 10-year period. Mov Disord 2002;17:1288–1293.PubMedCrossRefGoogle Scholar
  43. 43.
    Comella CL, Simpson L, Jankovic J. Botulinum toxins: transformation of a toxin into a treatment. In: Waxman SG, ed. Neuroscience, Molecular Medicine, and the Therapeutic Transformation of Neurology. Elsevier/Academic, 2004, in press.Google Scholar

Copyright information

© Humana Press Inc. 2005

Authors and Affiliations

  • Carolyn Kwak
    • 1
  • Joseph Jankovic
    • 1
  1. 1.Parkinson’s Disease Center and Movement Disorders Clinic, Department of NeurologyBaylor College of MedicineHouston

Personalised recommendations